Psych MEQs / SAQs · Consultation-liaison psychiatry
HD depression, irritability, suicide risk, and VMAT2 interface (MEQ)
FRANZCP-style MEQ on HD neuropsychiatry, suicide, irritability algorithms, and VMAT2 cautions.
On this page & tools
Target exams
Model answer
Reveal model answer
(i) Formulation and differentials. Leading cluster: major depression (biological symptoms, death wishes/burden beliefs) plus irritability/aggression (object throwing, short fuse) in manifest HD, with possible apathy overlap (sits unless prompted). Temporal link to tetrabenazine uptitration raises VMAT2-related dysphoria contribution.[1][5][8] Differentials: delirium (less likely without acute medical markers but consider aspiration/infection); pure apathy without depression; primary personality disorder (inadequate alone); substance use; medication toxicity; psychosis if paranoia emerges.[3][8]
(ii) Suicide risk. HD confers elevated suicidal ideation and behaviours; assess ideation, plan, intent, means (medication stockpile, weapons), past attempts, hopelessness, genetic 'curse' narrative, protective factors, and carer safety.[2][6] Acute steps: means restriction, increase supervision, crisis plan, consider hospital if intent/plan/high lethality or unsafe home, involve husband with consent/best-interest principles per local law (do not invent section numbers).[2][6]
(iii) Management. Joint neurology: review tetrabenazine dose/indication — TETRA-HD supports antichorea benefit but depression is a key adverse effect; reduce/stop if chorea allows or switch strategy.[5][7] Depression: start SSRI (e.g. sertraline 25–50 mg oral daily, titrate; or citalopram 10 mg oral daily with QTc/age caution); monitor activation and suicidality on initiation; sleep and psychological support.[3][7] Irritability: non-drug structure, carer education; SSRI often first drug step; if severe aggression persists, low-dose atypical (e.g. olanzapine 2.5–5 mg oral nocte or quetiapine 25 mg oral nocte) per expert algorithms, watch sedation/falls/rigidity.[3][4] For pure apathy components: OT/activation, not endless antidepressant stacking alone.[1][3]
(iv) Disposition. Multidisciplinary HD clinic follow-up (neurology, psychiatry, SLT for swallow, social work); genetics/family support for children at risk (no casual minor testing); advance care planning while capacity intact; carer support/respite; clear escalation for suicide or violence.[3][6][8]
Common errors
Common errors: ignoring tetrabenazine–depression link; calling everything 'understandable HD demoralisation'; missing suicide questions; high-dose haloperidol; testing asymptomatic children casually; inventing Mental Health Act sections; treating apathy as melancholia only.[2][3][5]
Examiner notes
High-scoring scripts name REGISTRY-level burden, suicide epidemiology, irritability algorithm (SSRI ± SGA), TETRA-HD/VMAT2 mood caution, and multidisciplinary HD care.[1][2][4][5]
References
- [1]van Duijn E, Craufurd D, Hubers AA, et al. Neuropsychiatric symptoms in a European Huntington's disease cohort (REGISTRY) J Neurol Neurosurg Psychiatry, 2014.PMID 24828898
- [2]Hubers AA, van Duijn E, Roos RA, et al. Suicidal ideation in a European Huntington's disease population J Affect Disord, 2013.PMID 23876196
- [3]Anderson KE, van Duijn E, Craufurd D, et al. Clinical Management of Neuropsychiatric Symptoms of Huntington Disease: Expert-Based Consensus Guidelines on Agitation, Anxiety, Apathy, Psychosis and Sleep Disorders J Huntingtons Dis, 2018.PMID 30040737
- [4]Groves M, van Duijn E, Anderson K, et al. An International Survey-based Algorithm for the Pharmacologic Treatment of Irritability in Huntington's Disease PLoS Curr, 2011.PMID 21975525
- [5]Huntington Study Group Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial Neurology, 2006.PMID 16476934
- [6]van Duijn E, Fernandes AR, Abreu D, et al. Incidence of completed suicide and suicide attempts in a global prospective study of Huntington's disease BMJ Ment Health, 2021.PMID 34462049
- [7]van Duijn E Medical treatment of behavioral manifestations of Huntington disease Handb Clin Neurol, 2017.PMID 28947111
- [8]Rosenblatt A Neuropsychiatry of Huntington's disease Dialogues Clin Neurosci, 2007.PMID 17726917